Article
Product categories and approval: separate the questions
How to evaluate peptide wellness claims · introductory evidence-reading guide, not a treatment guide.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
A molecule name is only part of a product's identity. For a regulatory statement, record the country, exact product, formulation, intended use, official source and date checked.
Compounding is a separate question
In the United States, compounded drugs are not FDA-approved. FDA does not assess their safety, effectiveness and quality through premarket approval. Compounding can address particular medical needs, for example when an FDA-approved drug cannot meet a particular patient's needs; its availability should not be described as product approval. Absence of FDA approval does not mean absence of all regulation. Applicable U.S. requirements still matter; this is not blanket permission to compound or a determination of legal eligibility. Compounding and the FDA: Questions and Answers Understanding the Risks of Compounded Drugs
Cosmetic and drug claims differ
Under the U.S. framework, intended use helps determine whether a product is a cosmetic, a drug, or both. A statement about appearance is not interchangeable with a claim to treat disease or change body structure or function. Is It a Cosmetic, a Drug, or Both?
Read regulatory information separately from research findings. Do not treat a label for one product as authorization for every preparation using a similar name. These U.S. statements are not rules for all the Americas. This introductory page is not an individual product-status determination or a purchasing guide.
U.S. regulatory information checked October 19, 2026 against the linked FDA sources. This is a review/access date, not the publication date of those sources or a legal certification. This overview does not determine whether an individual preparation is legally eligible for compounding or approved in another country.
Related reading
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- U.S. regulatory information. FDA. Understanding the Risks of Compounded Drugs. Accessed October 19, 2026.
- U.S. regulatory information. FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) Accessed October 19, 2026.
- U.S. regulatory information. FDA. Compounding and the FDA: Questions and Answers. Accessed October 19, 2026.
Related resources
Article · Module 1
What is a peptide? Structure, function, and evidence
The word peptide identifies a molecular structure. Understanding that structure is the starting point for asking better questions about biological function, research findings, and therapeutic claims.
Article · Module 1
How peptide receptors turn binding into a cellular response
A receptor is part of a signaling system. Binding, activation, amplification, and adaptation describe different stages, and each places limits on what an experimental finding can tell us.
Article · Module 1
Endogenous, synthetic, and recombinant peptides: what the labels mean
Origin and manufacturing method help describe a peptide, but they do not establish the quality or clinical performance of a finished product. Molecular identity and the conditions of exposure remain essential.